ECSP982525A - STABLE INSULIN FORMULATIONS - Google Patents
STABLE INSULIN FORMULATIONSInfo
- Publication number
- ECSP982525A ECSP982525A ECSP982525A ECSP982525A EC SP982525 A ECSP982525 A EC SP982525A EC SP982525 A ECSP982525 A EC SP982525A EC SP982525 A ECSP982525 A EC SP982525A
- Authority
- EC
- Ecuador
- Prior art keywords
- human insulin
- lis
- group
- cresol
- ala
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 5
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 4
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 abstract 3
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 abstract 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- 229930064664 L-arginine Natural products 0.000 abstract 1
- 235000014852 L-arginine Nutrition 0.000 abstract 1
- 239000007983 Tris buffer Substances 0.000 abstract 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 229960002242 chlorocresol Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- -1 insulin analog compound Chemical class 0.000 abstract 1
- 239000004026 insulin derivative Substances 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El invento se refiere a una formulación de solución que comprende: Un amortiguador fisiológicamente tolerado seleccionado del grupo consiste de TRIS y L-arginina; y un compuesto hexámero de análogo monomérico de insulina compuesto de: a) Seis moléculas de análogo de insulina humana, donde el análogo de insulina humana se selecciona a partir del grupo consiste de: (i) insulina humana donde Pro en la posición b28 es sustituida con Asp. Lis. Leu, Val o Ala y Lis en la posición B29 es Lis o Pro; (ii) insulina humana Ala B26; (iii) insulina humana des(B28-B30); e (iv) insulina humana des)B27); b)dos iones de zinc; y c) por lo menos tres moléculas de un preservativo fenólico seleccionado del grupo consistente de: (i) clorocreso; (ii) m-cresol; (iii) fenol, y (iv) mezclas de clorocresol, m-cresol y fenol.The invention relates to a solution formulation comprising: A physiologically tolerated buffer selected from the group consists of TRIS and L-arginine; and a hexameric monomeric insulin analog compound consisting of: a) Six molecules of human insulin analog, where the human insulin analog is selected from the group consisting of: (i) human insulin where Pro at position b28 is substituted with Asp. Lis. Leu, Val or Ala and Lis at position B29 is Lis or Pro; (ii) Ala B26 human insulin; (iii) des human insulin (B28-B30); and (iv) human insulin des) B27); b) two zinc ions; and c) at least three molecules of a phenolic preservative selected from the group consisting of: (i) chlorocrose; (ii) m-cresol; (iii) phenol, and (iv) mixtures of chlorocresol, m-cresol and phenol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982525 ECSP982525A (en) | 1998-06-10 | 1998-06-10 | STABLE INSULIN FORMULATIONS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982525 ECSP982525A (en) | 1998-06-10 | 1998-06-10 | STABLE INSULIN FORMULATIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP982525A true ECSP982525A (en) | 1999-01-26 |
Family
ID=42043446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP982525 ECSP982525A (en) | 1998-06-10 | 1998-06-10 | STABLE INSULIN FORMULATIONS |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP982525A (en) |
-
1998
- 1998-06-10 EC ECSP982525 patent/ECSP982525A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4750643A1 (en) | STABLE FORMULATION OF INSULIN CONTAINING L-ARGININ AND PROTAMINE | |
| CO4410203A1 (en) | INSULIN ANALOG FORMULATIONS | |
| AR039688A1 (en) | ACID INSULIN PREPARATIONS WITH IMPROVED STABILITY | |
| CO4410204A1 (en) | MONOMERIC INSULIN ANALOG FORMULATIONS | |
| BR9911579A (en) | Use of an antimicrobial compound for disinfection | |
| PE20000106A1 (en) | INSOLUBLE COMPOSITIONS TO CONTROL GLUCOSE IN THE BLOOD | |
| ES2177323T3 (en) | INSULIN PREPARATIONS CONCENTRATED STABLE FOR THE ADMINISTRATIONPOR VIA PULMONAR. | |
| EA200100458A1 (en) | Antiparasitic drugs | |
| DK0796082T3 (en) | Oral compositions containing stabilized tin compounds | |
| BRPI0112962B8 (en) | pharmaceutical compositions comprising hyaluronic acid, glycyrrhetinic acid and polyvinylpyrrolidone, and use of these compounds in the preparation of medicines | |
| PE20010709A1 (en) | METHODS AND SYSTEMS FOR THE TREATMENT OF ILL TISSUE WITH ANTIINFECTIVE COMPOSITIONS | |
| DE69000881D1 (en) | MEDICINE PREPARATION CONTAINING 2-PROPYLVALERIC ACID WITH DELAYED RELEASE OF THE ACTIVE SUBSTANCE. | |
| EP1852114A4 (en) | PREPARATION CONTAINING DIHOMO- (gamma) -LINOLENIC ACID (DGLA) AS ACTIVE INGREDIENT | |
| WO2002030467A3 (en) | Pharmaceutical composition containing honey for the treatment of wounds | |
| EA199901024A1 (en) | PHARMACEUTICAL ANTI-VIRUS COMPOSITION CONTAINING GLYCIRRIZIN ACID AND, AT LEAST MEASURES, ONE PROTEIN OWNED BY ANTI-VIRUS ACTIVITY | |
| ES2124983T5 (en) | USE OF AN SUBSTANCE ANTAGONIST P FOR THE TREATMENT OF RED CUTANEOUS STAINS OF NEUROGEN ORIGIN. | |
| PT93607A (en) | PROCESS FOR THE PREPARATION OF ECOLOGICAL PESTICIDES COMPOSITIONS CONTAINING A COMBINATION OF TENSIONIC AGENTS WITH A MICROEMULATION OF MINERAL AND / OR VEGETABLE OILS IN THE COLLOIDAL STATE | |
| BRPI0511707A (en) | calcium peroxyphosphates and their use in dental compositions | |
| WO2006062847A3 (en) | Compositions having a high antiviral and antibacterial efficacy | |
| ES2111102T3 (en) | COSMETIC AND DERMATOLOGIC FORMULATIONS WITH AN ACTIVE CONTENT IN CIS-UROCANINIC ACID. | |
| WO2004039326A3 (en) | Propofol with cysteine | |
| PT95212A (en) | A process for the preparation of a composition for topical use in the treatment of capillary fragility comprising defibrotide | |
| AR024094A1 (en) | CATALYTIC COMPOSITION AND THE PROCEDURE FOR THE DIMERIZATION AND OLIGOMERIZATION OF MONOOLEFINES WITH SUCH COMPOSITION. | |
| ES2055761T3 (en) | PROCEDURE FOR THE CONCENTRATION OF BLOOD COAGULATION FACTORS II, VII, IX AND X. | |
| AR016473A1 (en) | EFFECTIVE PREPARATION AND PROCEDURE FOR PREPARATION |